NAFLD合并T2DM患者糖化血红蛋白和甲状腺激素水平的变化及其临床意义*

doi:10.3969/j.issn.1672-5069.2020.02.015

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者糖化血红蛋白(HbA1C)和甲状腺激素水平的变化及其临床意义。方法 2017年4月～2019年3月我院内分泌科就诊的T2DM患者50例和NAFLD合并T2DM患者55例,检测人体学指标,采用电化学发光法检测空腹胰岛素(FINS)水平,采用胶体金法检测血糖化血红蛋白(HbA1C)水平,采用化学发光免疫分析法测定血清游离三碘甲状腺原氨酸(FT3)、游离四碘甲状腺原氨酸(FT4)和促甲状腺激素(TSH)水平。结果 NAFLD合并T2DM患者体质指数(BMI)为(28.4±2.7)kg/m²,显著大于T2DM患者【(24.0±2.4)kg/m²,P<0.05】,NAFLD合并T2DM患者腰围为(94.5±8.5)cm,显著大于T2DM患者【(84.0±7.6)cm,P<0.05】,NAFLD合并T2DM患者臀围为(97.1±8.0)cm,显著大于T2DM患者【(89.7±7.2)cm,P<0.05】;NAFLD合并T2DM患者血清谷丙转氨酶(ALT)水平为(79.5±7.6)U/L,显著高于T2DM患者【(42.3±4.3)U/L,P<0.05】,NAFLD合并T2DM患者血清谷草转氨酶(AST)水平为(59.7±6.1)U/L,显著高于T2DM患者【(41.2±3.9)U/L,P<0.05】,NAFLD合并T2DM患者血清谷氨酰转肽酶(GGT)水平为(105.8±9.4)U/L,显著高于T2DM患者【(60.9±6.5)U/L,P<0.05】;NAFLD合并T2DM患者血甘油三酯(TG)水平为(4.2±1.7) mmol/L,显著高于T2DM患者【(2.4±0.9)mmol/L,P<0.05】,NAFLD合并T2DM患者空腹血胰岛素(FINS)水平为(12.0±2.5)mU/L,显著大于T2DM患者【(9.1±1.8)mU/L,P<0.05】;NAFLD合并T2DM患者血清TSH水平为(3.4±1.2)mU/L,显著大于T2DM患者【(1.9±0.8)mU/L,P<0.05】,而两组FT3和FT4水平无显著性差异(P>0.05)。结论 NAFLD合并T2DM患者BMI、肝功能指标、TG、FINS和TSH水平均显著增大或升高,与T2DM患者有明显的不同,在临床诊治过程中应当有所甄别,深入研究NAFLD患者发病机制对诊治将大有裨益。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 糖化血红蛋白, 促甲状腺激素, 空腹胰岛素

Abstract: Objective The aim of this study was to investigate the changes of blood glycosylated hemoglobin(HbA1C) and thyroid hormone levels in patients with nonalcoholic fatty liver disease (NAFLD) complicated by type 2 diabetes mellitus (T2DM). Methods 50 patients with T2DM and 55 patients with NAFLD complicated byT2DM were recruited in the Department of Endocrinology in our hospital between April 2017 and March 2019, and all patients underwent somatology, serum liver and kidney function tests, blood lipids, HbA1C, fasting insulin (FINS), free triiodothyronine (FT3), free tetraiodothyronine(FT4) and thyroid stimulating hormone (TSH) were assayed. Results The body mass index (BMI) in patients with NAFLD complicated byT2DM was (28. 4±2.7) kg/m², significantly higher than [(24. 0±2.4) kg/m², P<0.05] in patients with T2DM, the waist circumference in patients with NAFLD and T2DM was (94.5±8.5) cm, significantly higher than(84.0_7.6) cm, P < 0.05)in patients with T2DM, and the hip circumference in patients with NAFLD complicated by T2DM was (97.1±8.0) cm, significantly higher than (89.7±7.2) cm, P<0.05) in T2DM patients;serum level of alanine aminotransferasein patients with NAFLD complicated by T2DM was (79.5±7.6) u/L, significantly higher than [(42.3±4.3) μ/L, P<0.05] in patients with T2DM, serum aspartate aminotransferase level in patients with NAFLD complicated by T2DM was (59.7±6.1) u/L, significantly higher than[(41.2±3.9) u/L, P<0.05] in patients with T2DM, and serum level of glutamyltranspeptidasein patients with NAFLD complicated byT2DM was (105.8±9.4) u/L, significantly higher than [(60.9±6.5) u/L, P<0.05] in patients with T2DM; blood triglyceride levelin patients with NAFLD complicated by T2DM was (4.2±1.7) mmol/L, significantly higher than [(2.4±0.9) mmol/L, P<0.05] in patients with T2DM, and blood level of fasting insulinin patients with NAFLD complicated by T2DM was (12.0±2.5) mU/L, significantly higher than [(9.1±1.8) mU/L, P<0.05] in patients with T2DM;serum level of thyroid stimulating hormone level in patients with NAFLD complicated byT2DM was (3.4±1.2) mU/L, significantly higher than [(1.9±0.8) mU/L, P<0.05] in patients with T2DM, while serum FT3 and FT4 levels in the two groups were not significantly different (P>0.05). Conclusion The BMI, serum liver function index, TG, FINS and TSH in patients with NAFLD complicated by T2DMchange greatly, significantly different as compared to in patients with T2DM,and clinicians should take these differences into consideration in clinical practice for early diagnosis and management.

Key words: Nonalcoholic fatty liver disease, Type 2 diabetes mellitus, Thyroid stimulating hormone, Fasting insulin, Glycosylated hemoglobin

刘继国, 窦翠云, 程广玲. NAFLD合并T2DM患者糖化血红蛋白和甲状腺激素水平的变化及其临床意义^*[J]. 实用肝脏病杂志, 2020, 23(2): 207-210.

Liu Jiguo, Dou Cuiyun , Cheng Guangling. Changes of blood glycosylated hemoglobin and thyroid hormone levels in patients with NAFLD complicated by T2DM[J]. Journal of Practical Hepatology, 2020, 23(2): 207-210.

参考文献

[1] Ahn SB, Jun DW, Kang BK, et al. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep, 2019, 9(1): 5688-5688.
[2] Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, 2018, 14(2): 88-98.
[3] 宋娜, 刘晓燕, 刘畅, 等. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义. 实用肝脏病杂志, 2019, 22(1): 65-68.
[4] Miyake T, Yoshida S, Furukawa S, et al. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Wars), 2018, 13: 402-409.
[5] Demir F,Şmşek FS, Ansal Balc T. The role of pre-ablative stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio for predicting metastasis in thyroid cancer. Mol Imaging Radionucl Ther, 2019, 28(1): 21-26.
[6] Verma S, Leiter LA, Mazer CD, et al. Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use. Circulation, 2018, 138(15): 1605-1607.
[7] de Gracia Hahn D, Duret A, Mann JP. An agtr1 variant worsens nonalcoholic fatty liver disease and the metabolic syndrome. Am J Gastroenterol, 2019, 114(4): 556-559.
[8] Mansour-Ghanaei F, Pourmasoumi M, Hadi A, et al. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: a systematic review of randomized controlled trials. Integr Med Res, 2019, 22(1): 57-61.
[9] Schumacher-Petersen C, Christoffersen B, Kirk RK, et al. Experimental non-alcoholic steatohepatitis in Gttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes. J Transl Med, 2019, 17(1): 110-110.
[10] 崔清华, 陶红, 王晓玥, 等. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究. 实用肝脏病杂志, 2019, 22(1): 69-71.
[10] Rubie C, Zimmer J, Lammert F, et al. Microrna-496 and mechanistic target of rapamycin expression are associated with type 2 diabetes mellitus and obesity in elderly people. Ann Nutr Metab, 2019, 74(4): 279-286.
[11] Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2019, 9(3): e017995.
[12] Mullish BH, Forlano R, Abeles RD, et al. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease - authors' reply. Aliment Pharmacol Ther, 2019, 49(8): 1093-1094.
[13] Deng XL, Ma R, Zhu HX, et al. A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 2017, 29(3): 297-301.
[14] van den Berg EH, Flores-Guerrero JL, Gruppen EG, et al. Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: role of circulating branched-chain amino acids. Nutrients, 2019, 11(3): 705-705.
[15] Mu W, Cheng XF, Liu Y, et al. Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues. Front Pharmacol, 2019, 9(1): 1566-1566.
[16] 胡利勋, 杨建全. 快步走联合太极拳锻炼对高龄非酒精性脂肪性肝病合并高血压患者血压和肝功能的影响. 实用肝脏病杂志, 2015, 18(5): 508-511.
[17] 邵庆华, 郑盛, 杨涓, 等. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平变化研究. 实用肝脏病杂志, 2016, 19(2): 175-179.
[18] Hu Y, Chen J, Yang L, et al. The value of neck circumference (nc) as a predictor of non-alcoholic fatty liver disease (nafld). J Clin Transl Endocrinol, 2014, 1(4): 133-139.
[19] Bril F, Kadiyala S, Portillo Sanchez P, et al. Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes. J Investig Med, 2016, 64(1): 63-8.
[20] 阎劲松, 袁丹, 李东升. 影响2型糖尿病患者新发非酒精性脂肪肝相关因素分析. 实用肝脏病杂志, 2016, 19(2): 212-214.

NAFLD合并T2DM患者糖化血红蛋白和甲状腺激素水平的变化及其临床意义^*

Changes of blood glycosylated hemoglobin and thyroid hormone levels in patients with NAFLD complicated by T2DM

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张猛, 陈晹, 刘娇, 李叶晟, 黄杨卿. 非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因FAS、ACC和SREBP-1水平分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 163-166.
[2]	姜佳丽, 李莉, 赵菲, 钟乐萍, 郭子皓, 张川, 展玉涛. 非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 167-170.
[3]	叶晓贤, 杨丽, 雷丽. 血清糖化血红蛋白和IL-6对非酒精性脂肪性肝病发病风险的预测价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 199-202.
[4]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[5]	曾震军, 李墨航. 血清学指标和脂肪肝指数诊断非酒精性脂肪性肝病价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 211-214.
[6]	王丽娟, 朱兵兵, 胡敏华, 杨丽, 石莉红, 胡健薇. 匹伐他汀与阿托伐他汀治疗非酒精性脂肪性肝病患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(2): 215-218.
[7]	任国亮, 李连生, 刘刚, 丰帆, 刘婧. 热量限制饮食对非酒精性脂肪性肝病患者胰岛素抵抗、血脂和氧化应激指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 219-222.
[8]	陈丽丽, 符茂雄, 蒙绪标, 方其超. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 38-41.
[9]	柳健, 朱峰发, 唐娟. 非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*[J]. 实用肝脏病杂志, 2020, 23(1): 42-45.
[10]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[11]	毛重山, 殷辉, 肖二辉, 张英英. 非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 50-53.
[12]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.
[13]	郭化磊, 卜理琳, 裴颖, 殷宏振, 黄峰. 化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化^*[J]. 实用肝脏病杂志, 2020, 23(1): 138-141.
[14]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[15]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.